Latest Advances in Lung Cancer Research

VA study reveals unique cancer patterns in Native American and Alaska Native veterans, informing tailored care and prevention efforts.

A study reveals that Black lung cancer patients are diagnosed younger and with more advanced stages than white patients, highlighting racial disparities in healthcare.

New US guidelines lower lung cancer screening age to 50 and reduce smoking history requirement to 20 pack-years, expanding preventative scans to save more lives.

The FDA granted orphan drug status to Quratusugene ozeplasmid, a promising gene-based therapy for small cell lung cancer, to expedite its development.

A recent multicenter study published in The Lancet highlights the promising efficacy of immunotherapy in advanced lung cancer patients.

The Monarch Platform robotic tool has revolutionized the way lung cancer is diagnosed and treated at Baptist Health. This cutting-edge technology provides a real-time, high-definition view of the airways, enabling doctors to identify and biopsy suspicious lung nodules with increased accuracy.

Scientists discover new link between air pollution and lung cancer, finding tiny particles trigger genetic changes, leading to new prevention and treatment opportunities.

Rybrevant plus chemo extends progression-free survival for newly diagnosed EGFR exon 20 patients, per study in Journal of Clinical Oncology.

A recent study sheds light on the challenges faced by black veterans when it comes to receiving timely referrals for lung cancer. The study, conducted by researchers from the University of Michigan and the VA Ann Arbor Healthcare System, examined the referral patterns for lung cancer among black and white veterans.

Dr. Steven Dubinett, member of LCFA’s Scientific Advisory Board, has been appointed as the new Dean of the David Geffen School of Medicine at the University of California, Los Angeles (UCLA). In this role, Dr. Dubinett will oversee the medical school’s operations and work towards advancing its mission of excellence in education, research, and patient care.

Bristol-Myers Squibb’s CheckMate-9LA trial shows combining nivolumab, ipilimumab, and chemotherapy improves outcomes in advanced NSCLC patients.